HK1245078A1 - 治療神經退行性疾病的方法 - Google Patents
治療神經退行性疾病的方法Info
- Publication number
- HK1245078A1 HK1245078A1 HK18104298.1A HK18104298A HK1245078A1 HK 1245078 A1 HK1245078 A1 HK 1245078A1 HK 18104298 A HK18104298 A HK 18104298A HK 1245078 A1 HK1245078 A1 HK 1245078A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treating
- methods
- neurodegenerative disease
- neurodegenerative
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applications Claiming Priority (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562158422P | 2015-05-07 | 2015-05-07 | |
US201562162060P | 2015-05-15 | 2015-05-15 | |
US201562162138P | 2015-05-15 | 2015-05-15 | |
US201562162068P | 2015-05-15 | 2015-05-15 | |
US201562162193P | 2015-05-15 | 2015-05-15 | |
US201562165034P | 2015-05-21 | 2015-05-21 | |
US201562167986P | 2015-05-29 | 2015-05-29 | |
US201562168246P | 2015-05-29 | 2015-05-29 | |
US201562169414P | 2015-06-01 | 2015-06-01 | |
US201562182225P | 2015-06-19 | 2015-06-19 | |
US201562189089P | 2015-07-06 | 2015-07-06 | |
US201562191189P | 2015-07-10 | 2015-07-10 | |
US201562201513P | 2015-08-05 | 2015-08-05 | |
US201562201494P | 2015-08-05 | 2015-08-05 | |
US201562239530P | 2015-10-09 | 2015-10-09 | |
US201562251534P | 2015-11-05 | 2015-11-05 | |
US201562256349P | 2015-11-17 | 2015-11-17 | |
US201562261115P | 2015-11-30 | 2015-11-30 | |
US201662289162P | 2016-01-29 | 2016-01-29 | |
US201662289643P | 2016-02-01 | 2016-02-01 | |
PCT/US2016/031359 WO2016179566A1 (en) | 2015-05-07 | 2016-05-06 | Methods of treating a neurodegenerative disease |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1245078A1 true HK1245078A1 (zh) | 2018-08-24 |
Family
ID=57217933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18104298.1A HK1245078A1 (zh) | 2015-05-07 | 2018-03-28 | 治療神經退行性疾病的方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160324852A1 (zh) |
EP (2) | EP3291816A4 (zh) |
JP (2) | JP2018515607A (zh) |
KR (2) | KR20180022661A (zh) |
CN (2) | CN107949386A (zh) |
AU (2) | AU2016256923A1 (zh) |
CA (2) | CA2985366A1 (zh) |
HK (1) | HK1245078A1 (zh) |
IL (2) | IL255421A0 (zh) |
MX (2) | MX2017014192A (zh) |
NO (2) | NO20171934A1 (zh) |
WO (2) | WO2016179569A1 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004000260T2 (de) | 2003-07-22 | 2006-08-24 | Arena Pharmaceuticals, Inc., San Diego | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
JP2018516992A (ja) | 2015-06-12 | 2018-06-28 | アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
RU2018103338A (ru) | 2015-07-15 | 2019-08-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием |
US20210346374A1 (en) * | 2016-10-03 | 2021-11-11 | Suven Life Sciences Limited | Pharmaceutical compositions of 5-ht6 receptor antagonist |
MA46836A (fr) * | 2016-11-15 | 2019-09-25 | H Lundbeck As | Agents, utilisations et procédés pour le traitement d'une synucléinopathie |
WO2018102824A1 (en) * | 2016-12-02 | 2018-06-07 | Axovant Sciences Gmbh | Methods for treating neurodegenerative disease |
BR112019001145A2 (pt) | 2017-05-24 | 2019-04-30 | H. Lundbeck A/S | combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para uso no tratamento da doença de alzheimer em uma subpopulação de pacientes portadores de alelos de apoe4 |
MX2019013198A (es) | 2017-06-01 | 2020-01-20 | Eisai R&D Man Co Ltd | Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9). |
EP3628315A1 (en) * | 2018-09-28 | 2020-04-01 | Université de Caen Normandie | Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases |
PL3906927T3 (pl) * | 2020-05-04 | 2022-07-25 | Bioprojet Pharma | Zastosowanie częściowych agonistów dopaminy D3 do leczenia zaburzeń ośrodkowego układu nerwowego |
AU2021304355A1 (en) * | 2020-07-10 | 2023-03-02 | Agenebio, Inc. | Polymorphs of a GABA |
CN112587534A (zh) * | 2020-12-23 | 2021-04-02 | 佑嘉(杭州)生物医药科技有限公司 | 阿伦酸在制备治疗肝纤维化药物中的用途 |
WO2023128900A1 (en) * | 2021-12-30 | 2023-07-06 | Pharmactive Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions comprising pimavanserin as active ingredient and relevant excipients |
WO2024040167A2 (en) * | 2022-08-18 | 2024-02-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Selective mc4r ligand for treating obesity and cognitive loss |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL209872B1 (pl) * | 2002-03-27 | 2011-10-31 | Glaxo Group Ltd | Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja |
JP5666087B2 (ja) * | 2005-04-06 | 2015-02-12 | アダマス・ファーマシューティカルズ・インコーポレーテッド | Cns関連疾患の治療のための方法及び組成物 |
PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
US20100120747A1 (en) * | 2006-06-23 | 2010-05-13 | Laboratorios Del Dr. Esteve, S.A. | Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity |
AR061637A1 (es) * | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
EP2508177A1 (en) * | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
ES2666324T3 (es) * | 2008-10-28 | 2018-05-04 | Arena Pharmaceuticals, Inc. | Composiciones de un modulador del receptor de serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con el mismo |
WO2011127235A1 (en) * | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
JO3459B1 (ar) * | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
-
2016
- 2016-05-06 WO PCT/US2016/031367 patent/WO2016179569A1/en active Application Filing
- 2016-05-06 JP JP2018510697A patent/JP2018515607A/ja active Pending
- 2016-05-06 CA CA2985366A patent/CA2985366A1/en not_active Abandoned
- 2016-05-06 KR KR1020177035169A patent/KR20180022661A/ko unknown
- 2016-05-06 CN CN201680036907.0A patent/CN107949386A/zh active Pending
- 2016-05-06 MX MX2017014192A patent/MX2017014192A/es unknown
- 2016-05-06 WO PCT/US2016/031359 patent/WO2016179566A1/en active Application Filing
- 2016-05-06 CN CN201680036847.2A patent/CN107847499A/zh active Pending
- 2016-05-06 CA CA2985370A patent/CA2985370A1/en not_active Abandoned
- 2016-05-06 JP JP2018510696A patent/JP2018519358A/ja active Pending
- 2016-05-06 EP EP16790213.9A patent/EP3291816A4/en not_active Withdrawn
- 2016-05-06 MX MX2017014191A patent/MX2017014191A/es unknown
- 2016-05-06 EP EP16790210.5A patent/EP3291815A4/en not_active Withdrawn
- 2016-05-06 AU AU2016256923A patent/AU2016256923A1/en not_active Abandoned
- 2016-05-06 US US15/149,053 patent/US20160324852A1/en not_active Abandoned
- 2016-05-06 AU AU2016258198A patent/AU2016258198A1/en not_active Abandoned
- 2016-05-06 KR KR1020177035167A patent/KR20180021693A/ko unknown
-
2017
- 2017-11-05 IL IL255421A patent/IL255421A0/en unknown
- 2017-11-05 IL IL255423A patent/IL255423A0/en unknown
- 2017-12-05 NO NO20171934A patent/NO20171934A1/en not_active Application Discontinuation
- 2017-12-05 NO NO20171941A patent/NO20171941A1/en not_active Application Discontinuation
-
2018
- 2018-03-28 HK HK18104298.1A patent/HK1245078A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2016179566A1 (en) | 2016-11-10 |
US20160324852A1 (en) | 2016-11-10 |
MX2017014192A (es) | 2018-08-01 |
AU2016256923A1 (en) | 2017-11-23 |
JP2018515607A (ja) | 2018-06-14 |
NO20171934A1 (en) | 2017-12-05 |
IL255423A0 (en) | 2017-12-31 |
EP3291816A4 (en) | 2019-01-02 |
KR20180022661A (ko) | 2018-03-06 |
CN107847499A (zh) | 2018-03-27 |
CA2985370A1 (en) | 2016-11-10 |
EP3291815A4 (en) | 2019-01-16 |
EP3291815A1 (en) | 2018-03-14 |
NO20171941A1 (en) | 2017-12-05 |
KR20180021693A (ko) | 2018-03-05 |
CN107949386A (zh) | 2018-04-20 |
IL255421A0 (en) | 2017-12-31 |
EP3291816A1 (en) | 2018-03-14 |
WO2016179569A1 (en) | 2016-11-10 |
MX2017014191A (es) | 2018-08-01 |
AU2016258198A1 (en) | 2017-11-23 |
CA2985366A1 (en) | 2016-11-10 |
JP2018519358A (ja) | 2018-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1245078A1 (zh) | 治療神經退行性疾病的方法 | |
HK1252568A1 (zh) | 一種治療方法 | |
IL269106A (en) | Methods for the treatment of neurodegenerative diseases | |
HK1252996A1 (zh) | 用於治療癲癇的方法 | |
SI3393468T1 (sl) | Postopki za zdravljenje bolezni imunske pomanjkljivosti | |
HK1252692A1 (zh) | 治療或者預防蛋白質構象病的方法 | |
HK1251965A1 (zh) | 用於治療癲癇的方法 | |
GB201522243D0 (en) | Treatment | |
GB201401430D0 (en) | Treatment process | |
GB201502137D0 (en) | Treatment | |
HK1258994A1 (zh) | 用於疾病治療的方法 | |
HK1247818A1 (zh) | 治療疾病的方法 | |
GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
GB201410116D0 (en) | Method of treatment | |
SG10201912688YA (en) | A method of treatment | |
IL253028A0 (en) | treatment method | |
SG11201609522TA (en) | Methods for treating cardiovascular diseases | |
GB201521886D0 (en) | A method of treating a well | |
GB201508841D0 (en) | Treatment | |
HK1250243A1 (zh) | 治療方法 | |
HK1243937A1 (zh) | 治療疾病的方法 | |
HK1246679A1 (zh) | 絲蟲病的治療 | |
GB201420348D0 (en) | Compounds for treating neurodegenerative diseases | |
GB201512139D0 (en) | Methods of treatment | |
GB201503008D0 (en) | Treatment |